


Q3 2026

Psychedelic Drug Development Bullseye Charts

© Psychedelic Alpha, 2026.

Supported by





© Psychedelic Alpha, 2026.

© Psychedelic Alpha, 2026.

Psychedelic Drug Development Tracker

BY INDICATION GROUPING


Depressive Disorders

Anxiety Disorders

Substance Use Disorders

PTSD

Other



Supported by



Abbreviations: ASD: Autism Spectrum Disorder; AUD: Alcohol Use Disorder; BD: Bipolar Depression; BDII: Bipolar 2 Disorder; **BTD**: FDA Breakthrough Therapy Designation; **CNPV**: FDA Commissioner's National Priority Voucher; GAD: Generalised Anxiety Disorder; IM: Intramuscular; IV: Intravenous; MDD: Major Depressive Disorder; OCD: Obsessive Compulsive Disorder; ODT: Orally Disintegrating Tablet; OTF: Oral Thin Film; OUD: Opioid Use Disorder; PPD: Postpartum Depression; PTSD: Post-Traumatic Stress Disorder; SAD: Social Anxiety Disorder; SC: Subcutaneous; SL: Sublingual; StUD: Stimulant Use Disorder; SUDs: Substance Use Disorders; TRD: Treatment-Resistant Depression; XR: Extended Release; * At the time of publishing, this deal has been announced by both AtaiBeckley and Eli Lilly, but has not yet closed.

